CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 335 enrolled
Drug / intervention
Clopidogrel +1 moredrug
Likely dose
Clopidogrel 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01235351
NCT01235351Phase 2Completed
CompareCT.gov

Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56

The TIMI Study Group·interventional·Posted Nov 5, 2010·Updated Nov 15, 2019

In Brief

A Phase 2 clinical trial evaluating Clopidogrel for Myocardial Infarction and Percutaneous Coronary Intervention. Completed, enrolled 335 participants across 1 site.

Detailed Summary

To determine whether higher as compared with lower maintenance doses of clopidogrel can adequately improve the degree of platelet inhibition in carriers of a reduced-function CYP2C19 allele.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyocardial Infarction, Percutaneous Coronary Intervention
CountriesUnited States
CollaboratorsBristol-Myers Squibb, Sanofi

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 5, 2010
Enrollment StartOct 1, 2010
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 15.7 years ago

Interventions

Clopidogreldrug

Clopidogrel 75 mg daily, 150 mg daily, 225 mg daily, and 300 mg daily based on genotype

Clopidogreldrug

Clopidogrel 75 mg daily, 150 mg daily